Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 3/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MLYCD | O95822 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20674797 | 0.82 | DNM1 (0.44) | EPHX2HDAC1HDAC2HDAC6DNM1 | |
| SCHEMBL25495940 | 0.80 | DNM1 (0.47) | EPHX2HDAC1HDAC2HDAC6DNM1 | |
| SCHEMBL19085527 | 0.80 | TSHR (0.52) | LMNACA7DNM1CA14CA12 | |
| SCHEMBL30073985 | 0.80 | DNM1 (0.47) | EPHX2HDAC1HDAC2HDAC6DNM1 | |
| SCHEMBL24262297 | 0.80 | DNM1 (0.32) | LMNADNM1 | |
| SCHEMBL134923 | 0.79 | EPHX2 (0.46) | EPHX2HDAC1HDAC2HDAC6LMNA | |
| SCHEMBL20674791 | 0.79 | CA1 (0.35) | EPHX2HDAC1HDAC2HDAC6LMNA | |
| SCHEMBL25634868 | 0.77 | KDM5A (0.46) | EPHX2HDAC1HDAC2HDAC6CA1 | |
| SCHEMBL14482719 | 0.77 | EPHX2 (0.49) | EPHX2HDAC1HDAC2HDAC6LMNA | |
| SCHEMBL20450540 | 0.77 | EPHX2 (0.49) | EPHX2HDAC1HDAC2HDAC6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372537-A1 | LIPID NANOPARTICLE FORMULATIONS | ACUITAS THERAPEUTICS INC (CA) | 2023-11-23 | — | — | US | disclosed |
| US-11771715-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11766449-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11712481-B2 | Lipid nanoparticle formulations | Acuitas Therapeutics, Inc. (CA) | 2023-08-01 | — | — | US | disclosed |
| US-20230226096-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-11679120-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11712481-B2 | Lipid nanoparticle formulations | LIPA, PLIN3, PLIN1 | EPHX2 1934/4885HDAC1 1105/4885HDAC2 1383/4885 |
| US-20230372537-A1 | LIPID NANOPARTICLE FORMULATIONS | LIPA, PLIN3, PLIN1 | EPHX2 1934/4885HDAC1 1105/4885HDAC2 1383/4885 |
| US-11771715-B2 | Circular RNA compositions and methods | RTCB, HNRNPA1, HNRNPAB | EPHX2 3620/4885HDAC1 3991/4885HDAC2 3328/4885 |
| US-20230226096-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | RTCB, HNRNPA1, HNRNPAB | EPHX2 3620/4885HDAC1 3991/4885HDAC2 3328/4885 |
| US-11679120-B2 | Circular RNA compositions and methods | RTCB, HNRNPA1, HNRNPAB | EPHX2 3620/4885HDAC1 3991/4885HDAC2 3328/4885 |
| US-11766449-B2 | Circular RNA compositions and methods | RTCB, RNGTT, HNRNPAB | EPHX2 3850/4885HDAC1 4195/4885HDAC2 3607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.